Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | ALB | P02768 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1004620 | 0.82 | ALDH1A1 (0.52) | GRM5ALDH1A1CYP2A6TTRALB | |
| SCHEMBL56741 | 0.82 | GRM5 (0.43) | GRM5TTRALB | |
| SCHEMBL1421650 | 0.82 | GRM5 (0.47) | GRM5 | |
| SCHEMBL501406 | 0.82 | ALDH1A1 (0.52) | GRM5ALDH1A1CYP2A6TTRALB | |
| SCHEMBL28896868 | 0.76 | ACHE (0.36) | GRM5 | |
| SCHEMBL26377782 | 0.76 | ACHE (0.36) | GRM5 | |
| SCHEMBL16959665 | 0.76 | ACHE (0.36) | GRM5 | |
| SCHEMBL16952991 | 0.76 | ACHE (0.36) | GRM5 | |
| SCHEMBL4459781 | 0.76 | GRM5 (0.49) | GRM5 | |
| SCHEMBL4454176 | 0.76 | ALDH1A1 (0.54) | GRM5ALDH1A1CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 256 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3887359-B1 | NOVEL TETRAZINE COMPOUNDS FOR IN VIVO IMAGING | UNIV COPENHAGEN (DK) | 2026-05-06 | — | — | EP | disclosed |
| EP-3768269-B1 | COMPOUNDS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2025-08-20 | — | — | EP | disclosed |
| US-20250122171-A1 | Substituted Amine Compounds, Compositions and Methods of Use | DEEP APPLE THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| WO-2025064534-A1 | SUBSTITUTED AMINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | DEEP APPLE THERAPEUTICS, INC. (US) | 2025-03-27 | — | — | WO | disclosed |
| US-12180221-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-12-31 | — | — | US | disclosed |
| US-20240287104-A1 | NUCLIDE LABELLED H-TETRAZINES AND USE THEREOF FOR PET AND SPECT PRETARGETED IMAGING AND RADIONUCLIDE THERAPY | RIGSHOSPITALET [DK]/[DK] (DK) | 2024-08-29 | — | — | US | disclosed |
| EP-4400172-A2 | PIPERIDIN-4-YL AZETIDINE DERIVATIVES AS JAK1 INHIBITORS | Incyte Holdings Corporation (US) | 2024-07-17 | — | — | EP | disclosed |
| CN-118084800-A | Compounds and uses thereof | 詹森药业有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-118084801-A | Compounds and uses thereof | 詹森药业有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-112312913-B | Compounds and uses thereof | 詹森药业有限公司 | 2024-03-08 | — | — | CN | disclosed |
| WO-2009000819-A1 | 5-PHENYL-1,3,4-OXADIAZOL-2-YL-ACETYL-4-PIPERIDINYL DERIVATIVES AS CGRP RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2008-12-31 | — | — | WO | disclosed |
| US-20080194694-A1 | nematocides such as N-{1-cyano-2-[5-cyano-2-(trifluoromethyl)phenoxy]-1-methylethyl}-4-pentafluorothiobenzamide, tautomers or prodrugs, carriers and optionally a second therapeutic agent, used for treating parasitic infestations | PFIZER LIMITED (UK) | 2008-08-14 | — | — | US | disclosed |
| CN-101151249-A | Cyclopentapyridine and tetrahydroquinoline derivatives | PFIZER (US) | 2008-03-26 | — | — | CN | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| WO-2007062314-A2 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007062308-A2 | HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007062342-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
| US-20070020479-A1 | Luminescent-polymer composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-01-25 | — | — | US | disclosed |
| US-20070020479-A1 | Luminescent-polymer composition | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-01-25 | — | — | US | disclosed |
| US-20060247254-A1 | Cyclopentapyridine and tetrahydroquinoline derivatives | PFIZER. INC | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194694-A1 | nematocides such as N-{1-cyano-2-[5-cyano-2-(trifluoromethyl)phenoxy]-1-methylethyl}-4-pentafluorothiobenzamide, tautomers or prodrugs, carriers and optionally a second therapeutic agent, used for treating parasitic infestations | HRH4, HRH3, HRH2 | GRM5 1686/4885ALDH1A1 3124/4885CYP2A6 2752/4885 |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | GRM5 4870/4885ALDH1A1 2353/4885CYP2A6 867/4885 |
| US-20250122171-A1 | Substituted Amine Compounds, Compositions and Methods of Use | MRGPRX2, MRGPRX1, MRGPRX4 | GRM5 83/4885ALDH1A1 2569/4885CYP2A6 2144/4885 |
| US-20060247254-A1 | Cyclopentapyridine and tetrahydroquinoline derivatives | HTR2C, HTR2A, HTR5A | GRM5 106/4885ALDH1A1 1415/4885CYP2A6 523/4885 |
| US-20240287104-A1 | NUCLIDE LABELLED H-TETRAZINES AND USE THEREOF FOR PET AND SPECT PRETARGETED IMAGING AND RADIONUCLIDE THERAPY | HUNK, NUCB2, TK1 | GRM5 2620/4885ALDH1A1 2499/4885CYP2A6 4728/4885 |
| US-12180221-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | GRM5 68/4885ALDH1A1 656/4885CYP2A6 1182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.